CT-023 is under clinical development by Shenzhen Xiankangda Life Sciences and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CT-023’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CT-023 overview

CT-023 is under development for the treatment of CD19 positive recurrent or refractory diffuse large B cell lymphoma, solid tumor, lung cancer, ovarian cancer, esophageal cancer, stomach cancer, pancreatic cancer, endometrial cancer, cervical cancer, breast thyroid cancer, colorectal cancer, prostate cancer. The therapeutic candidate comprises T-cells genetically engineered to express chimeric antigen receptor (CAR) targeting cells expressing CD19.

Shenzhen Xiankangda Life Sciences overview

Shenzhen Xiankangda Life Sciences (Xiankangda Life Sciences) operate in healthcare sector. Xiankangda Life Sciences is headquartered in Shenzhen, Guangdong, China.

For a complete picture of CT-023’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.